• Tues news: Prostate cancer trials to watch. Merck’s subcutaneous Keytruda. Apellis sees positive in Astellas CRL. Future of Medicare price negotiations. JNJ psoriasis results. See more on our front page

CCRs interviewing for Amgen or Sanofi









Most likely Sanofi and Pfizer will do better in this market.

Also, Amgen's heart failure drug, Ivabradine, has bad press (which will spill over to their PCSK9 drug Evolocumab), while Novartis' heart failure drug (LCZ696) is receiving accolades.

Amgen reps will not have it easy.